Company | HCA Healthcare, Inc. (NYSE: HCA) |
Upcoming Earnings Call | July 24, 2026 — 10:00 AM ET (9:00 AM CT) |
Reporting Period | Q2 2026 (quarter ended June 30, 2026) |
Preparation Date | July 23, 2026 |
Preannouncement Date | July 14, 2026 (preliminary Q2 results + FY2026 guidance cut) |
⚠️ Important Context: HCA preannounced preliminary Q2 2026 results and lowered full-year 2026 guidance on July 14, 2026 — ten days before the formal earnings call. The preliminary figures are subject to finalization of quarterly financial and accounting procedures. This document is therefore a call preview, not a traditional earnings preview: the headline numbers are already known, and the July 24 call will focus on management's explanation of the payer-mix deterioration, the revised guidance framework, and the outlook for H2 2026.
Key Takeaway: The bar is already set — HCA preannounced Q2 EPS of $7.62 (above the prior $7.47 consensus) and revenue of $20.23B (well above the $19.41B consensus) — but the stock sold off ~10% on July 14 because management simultaneously cut full-year EPS guidance by ~$0.90 at the midpoint, citing a $400M unfavorable Q2 payer-mix impact from ACA exchange disenrollment. The July 24 call is about the magnitude and durability of that headwind, not the Q2 beat.
Heading into the July 24 call, the setup is unusual: HCA beat Q2 consensus on every headline metric yet guided the stock sharply lower, creating a situation where the market is pricing in a structurally worse business rather than a one-quarter miss. The company raised its estimate of the full-year ACA exchange headwind to $1.0–$1.2B (from $0.6–$0.9B) on income before taxes, driven by a Q2 payer-mix shift that was roughly double the Q1 run-rate impact. Partially offsetting this, the Florida Medicaid state-directed payment program was approved by CMS during Q2, contributing approximately $400M of incremental supplemental payment benefit (covering October 2024 through June 2026), which is now embedded in the revised guidance. Estimate revisions have moved modestly lower since the preannouncement — FY2026 consensus EPS sits at ~$30.00 vs. the new guidance midpoint of $29.60 — suggesting the Street has not yet fully capitulated to the low end of guidance. The stock has de-rated sharply over the past three months (NTM P/E compressed from ~15x to ~12x), so the multiple is no longer stretched, but the wildcard is whether management signals that the H2 exchange headwind is stabilizing or still accelerating — any commentary suggesting the $1.0–$1.2B range is a ceiling rather than a floor would be the single biggest positive catalyst on the call.
Key Takeaway: Q2 headline metrics beat consensus on revenue and EPS, but the beat was overshadowed by a ~200 bps Adjusted EBITDA margin miss vs. prior-year (19.9% vs. 20.7%) driven by the payer-mix shift. Equivalent admissions growth of +2.7% same-store was solid, but surgical volume declines (−2.3% inpatient, −3.4% outpatient) are the bigger swing factor for H2.
KPI | Q1 2026 Actual (Last Quarter) | Q2 2025 Actual (Prior Year) | Q2 2026 Preliminary / Consensus | YoY Change | FY2026 Guidance (Revised Jul 14) | Consensus vs. Guidance Midpoint |
Total Revenues ($B) | $19.109B | $18.605B | $20.230B (prelim)¹ / $19.759B (VA cons.)¹ | +8.7% YoY | $77.0–$79.5B (mid: $78.25B) | VA FY cons. $78.44B ≈ +0.2% vs. mid |
Adjusted EBITDA ($B) | $3.802B | $3.849B | $4.027B (prelim)¹ / $4.007B (VA cons.)¹ | +4.6% YoY | $15.4–$16.1B (mid: $15.75B) | VA FY cons. $15.84B ≈ +0.6% vs. mid |
Adj. EBITDA Margin (%) | 19.9% | 20.7% | 19.9% (prelim)¹ | − 80 bps YoY | ~20.1% implied (mid) | Prelim in line with guidance mid |
Diluted EPS — Operating ($) | $7.15 | $6.84 | $7.62 (prelim)¹ / $7.57 (VA cons.)¹ | +11.4% YoY | $28.70–$30.50 (mid: $29.60) | VA FY cons. $30.00 ≈ +1.4% vs. mid |
Same-Facility Equiv. Admissions Growth (%) | +1.3% | +1.7% | +2.7% (prelim)¹ / +2.3% (VA cons.)¹ | +100 bps vs. Q2 2025 | ~2–3% FY range (mgmt) | Prelim above VA cons. |
Same-Facility Inpatient Surgery Growth (%) | −0.3% | N/A — not in VA | −2.3% (prelim)¹ | Deteriorated vs. Q1 | N/A | N/A |
Same-Facility Outpatient Surgery Growth (%) | −1.7% | N/A — not in VA | −3.4% (prelim)¹ | Deteriorated vs. Q1 | N/A | N/A |
Same-Facility ER Visits Growth (%) | +0.3% | N/A — not in VA | +3.6% (prelim)¹ | Accelerated vs. Q1 | N/A | N/A |
¹ Preliminary Q2 2026 figures from HCA's July 14, 2026 preannouncement (subject to finalization). VA consensus figures from Visible Alpha Consensus and Actuals Data.
Quarter | KPI | Reported | Consensus | Surprise % | Result |
Q3 2024 | Adj. EPS | $4.90 | $4.98 | −1.6% | Miss |
Q3 2024 | Adj. EBITDA | $3.267B | $3.292B | −0.8% | Miss |
Q4 2024 | Adj. EPS | $6.22 | $6.07 | +2.5% | Beat |
Q4 2024 | Adj. EBITDA | $3.712B | $3.669B | +1.2% | Beat |
Q1 2025 | Adj. EPS | $6.45 | $5.77 | +11.8% | Beat |
Q1 2025 | Adj. EBITDA | $3.733B | $3.526B | +5.9% | Beat |
Q2 2025 | Adj. EPS | $6.84 | $6.27 | +9.1% | Beat |
Q2 2025 | Adj. EBITDA | $3.849B | $3.701B | +4.0% | Beat |
Q3 2025 | Adj. EPS | $6.96 | $5.66 | +22.9% | Beat |
Q3 2025 | Adj. EBITDA | $3.870B | $3.457B | +11.9% | Beat |
Q4 2025 | Adj. EPS | $8.01 | $7.49 | +6.9% | Beat |
Q4 2025 | Adj. EBITDA | $4.114B | $4.045B | +1.7% | Beat |
Q1 2026 | Adj. EPS | $7.15 | $7.16 | −0.1% | In Line / Slight Miss |
Q1 2026 | Adj. EBITDA | $3.802B | $3.874B | −1.9% | Miss |
Q2 2026 (Prelim) | Adj. EPS | $7.62¹ | $7.45¹ | +2.3% | Beat (prelim) |
Q2 2026 (Prelim) | Adj. EBITDA | $4.027B¹ | $3.971B¹ | +1.4% | Beat (prelim) |
Pattern: HCA beat on Adj. EPS in 6 of the last 8 quarters and on Adj. EBITDA in 5 of 8, with the two misses (Q3 2024 and Q1 2026) both driven by identifiable one-time volume headwinds (managed care repricing and respiratory/weather, respectively). The Q2 2026 preliminary beat is real but market-irrelevant given the guidance cut. Source: Visible Alpha Consensus and Actuals Data; ¹ Q2 2026 preliminary figures from HCA July 14, 2026 preannouncement.
Key Takeaway: Management cut full-year 2026 guidance on July 14 — the first formal reduction since the January 27 initial issuance — driven entirely by the ACA exchange payer-mix headwind, which nearly doubled from the Q1 estimate. The supplemental payment assumption improved materially (Florida DPP approved), partially cushioning the cut. Tone has shifted from “confident we can navigate” (April 24) to “adjusted to reflect these factors” (July 14).
Metric | Initial Guidance (Jan 27, 2026) | Q1 Reaffirmation (Apr 24, 2026) | Revised Guidance (Jul 14, 2026) | Current VA Consensus | Note |
Total Revenues | $76.5–$80.0B | Reaffirmed | $77.0–$79.5B | $78.44B | ↓ Narrowed Jul 14; range tightened, midpoint up $0.25B vs. initial |
Adjusted EBITDA | $15.55–$16.45B | Reaffirmed | $15.4–$16.1B | $15.84B | ↓ Cut Jul 14; midpoint down ~$225M; margin pressure from payer mix |
Diluted EPS (Operating) | $29.10–$31.50 | Reaffirmed | $28.70–$30.50 | $30.00 | ↓ Cut Jul 14; midpoint down ~$0.90; consensus above midpoint |
Net Income Attr. to HCA | $6.495–$7.035B | Reaffirmed | $6.300–$6.700B | N/A — not in VA | ↓ Cut Jul 14; midpoint down ~$265M |
CapEx (excl. acquisitions) | $5.0–$5.5B | Reaffirmed | Unchanged: $5.0–$5.5B | N/A — not in VA | Unchanged; management maintaining growth investment despite headwinds |
ACA Exchange Impact (income before taxes) | ($600)–($900)M | Reaffirmed ($600)–($900)M | ($1,000)–($1,200)M | N/A | ↓ Worsened Jul 14; Q2 alone was ~$400M impact; includes ~$75M Q1 true-up |
Medicaid Supplemental Payments (net benefit vs. PY) | ($250)–($450)M decline | ($50)–($250)M decline (GA + TX approved) | +$300–+$500M benefit | N/A | ↑ Improved Jul 14; Florida DPP approved by CMS in Q2 (~$400M Q2 benefit) |
Key Takeaway: Since the Q1 print on April 24, FY2026 EPS consensus has drifted down ~1.5% and now sits ~$0.40 above the revised guidance midpoint of $29.60 — suggesting the Street has not fully moved to the low end of the new range. The Q2 2026 consensus was already tracking above the preliminary actual, meaning the beat was priced in. The risk is that H2 estimates need to come down further if the exchange headwind does not stabilize.
KPI (Period) | Estimate ~5 Days Post Q1 Print (c. May 1, 2026) | Current Consensus (Jul 23, 2026) | Estimate Δ (%) | Initial Guidance (Jan 27 / Apr 24) | Current Guidance (Jul 14, 2026) | Guidance Δ | Consensus vs. Guidance Mid (%) |
Adj. EPS — Q2 2026 | $7.45 | $7.57 | +1.6% | N/A (quarterly) | N/A (quarterly) | N/A | Prelim $7.62 = +0.7% vs. cons. |
Adj. EBITDA — Q2 2026 | $3.971B | $4.007B | +0.9% | N/A (quarterly) | N/A (quarterly) | N/A | Prelim $4.027B = +0.5% vs. cons. |
Total Revenue — Q2 2026 | $19.363B | $19.759B | +2.1% | N/A (quarterly) | N/A (quarterly) | N/A | Prelim $20.23B = +2.4% vs. cons. |
Adj. EPS — FY2026 | $30.30 | $30.00 | −1.0% | $29.10–$31.50 (mid $30.30) | $28.70–$30.50 (mid $29.60) | −2.3% at mid | +1.4% above new mid; risk to downside |
Adj. EBITDA — FY2026 | $15.964B | $15.839B | −0.8% | $15.55–$16.45B (mid $16.00B) | $15.4–$16.1B (mid $15.75B) | −1.6% at mid | +0.6% above new mid; modest cushion |
Total Revenue — FY2026 | $78.522B | $78.439B | −0.1% | $76.5–$80.0B (mid $78.25B) | $77.0–$79.5B (mid $78.25B) | Unchanged at mid | +0.2% above new mid; in line |
SS Equiv. Admissions Growth — Q2 2026 | 2.10% | 2.31% | +10 bps | 2–3% FY range | 2–3% FY range (unchanged) | Unchanged | Prelim +2.7% above cons.; positive |
The key divergence: FY2026 EPS consensus at $30.00 sits $0.40 above the new guidance midpoint of $29.60, implying the Street is not yet at the midpoint of management's own revised range. If the July 24 call signals that the H2 exchange headwind is tracking toward the high end of the $1.0–$1.2B range, further estimate cuts are likely. Source: Visible Alpha Consensus and Actuals Data; guidance from HCA July 14, 2026 preannouncement and April 24, 2026 Q1 earnings release.
Key Takeaway: HCA has underperformed both XLV and the S&P 500 by a wide margin since the Q1 print on April 24, driven almost entirely by multiple compression (NTM P/E from ~15x to ~12x, NTM EV/EBITDA from ~9.5x to ~8.2x) rather than estimate cuts alone — the market is repricing the business for a structurally worse payer mix, not just a one-quarter miss.
Since the Q1 2026 earnings close on April 24, 2026 ($432.46), HCA has declined approximately −13.0% to $376.50 (July 24, 2026), while XLV (Health Care Select Sector SPDR ETF) has risen approximately +11.9% and the S&P 500 (SPY) has risen approximately +3.4%. The most significant single-day event was July 14, 2026, when HCA fell approximately −9.4% on the preannouncement and guidance cut. The stock partially recovered in the days following but remains well below pre-preannouncement levels. The 3-month NTM EV/EBITDA compression of ~−13.6% (from 9.48x to 8.19x) confirms that the de-rating is multiple-driven, not estimate-driven. Source: Stock Price Data (Yahoo Finance); Stock Performance Decomposition Data.
Key Events Marked on Chart:
Date | HCA Close | HCA Indexed (Base 100) | XLV Indexed | SPY Indexed |
Apr 24, 2026 (Base) | $432.46 | 100.0 | 100.0 | 100.0 |
May 1, 2026 | $433.09 | 100.1 | 100.7 | 100.9 |
May 19, 2026 | $404.69 | 93.6 | 102.2 | 102.8 |
Jun 18, 2026 (CCO departure) | $375.17 | 86.8 | 103.6 | 104.6 |
Jul 7, 2026 (Pre-preannouncement high) | $423.11 | 97.8 | 114.1 | 104.7 |
Jul 14, 2026 (Preannouncement) | $363.60 | 84.1 | 109.8 | 105.3 |
Jul 24, 2026 (Latest) | $376.50 | 87.1 | 111.9 | 103.4 |
Note: XLV (Health Care Select Sector SPDR ETF) is used as the sector benchmark — it is the most widely used healthcare sector ETF and appropriate for HCA's hospital/managed care sub-sector. Source: Stock Price Data (Yahoo Finance).
Key Takeaway: The July 14 preannouncement and guidance cut is the dominant event since Q1 earnings — it revealed that the ACA exchange headwind is materially larger than guided, and the stock's ~13% decline since April 24 reflects a structural re-rating, not a temporary setback.
Key Takeaway: CYH's July 22–23 Q2 2026 earnings are the most directly relevant peer read-through: they confirm the ACA exchange disenrollment trend is real and worsening, that surgical volume softness is broad-based and linked to consumer affordability, and that payer-mix headwinds are accelerating into H2. THC's Q2 beat is a partial offset but reflects a structurally different business mix.
Scope Note: This section includes ONLY commentary that explicitly relates to Q2 2026 (current-quarter) operating conditions. Prior-quarter results (Q1 2026 earnings calls from peers) and non-operational filings (shareholder meetings, credit amendments) are excluded. THC's Q2 2026 results are referenced in Material News but are not yet available as a full transcript for detailed read-through analysis as of July 23, 2026.
Source: CYH Q2 2026 Earnings Release (July 22, 2026) and Q2 2026 Earnings Call Transcript (July 23, 2026). CYH is a direct hospital operator peer with a national footprint, making it the most relevant read-through for HCA's inpatient volume, payer mix, and cost trends.
Theme | CYH Q2 2026 Commentary (Current Quarter) | HCA Read-Through | Limitations / Caveats |
ACA Exchange Disenrollment | CYH saw a more significant decline in exchange volumes in Q2 vs. Q1, with a direct correlation to an increase in self-pay. Q2 EBITDA impact was ~$20M; H1 total ~$25M. CYH now expects $50–$75M full-year EBITDA impact (vs. initial $20–$30M). The initial assumption that those who lost coverage would exit the health system was incorrect — they continue to utilize services at similar rates but as uninsured, driving higher costs with minimal net revenue. | Strongly confirms HCA's experience. HCA's Q2 exchange impact of ~$400M (income before taxes) is proportionally much larger, consistent with HCA's greater exchange exposure (~8% of admissions, ~10% of revenue). The pattern of exchange patients converting to uninsured rather than exiting the system is a key insight for HCA's uncompensated care trajectory. | CYH's exchange exposure is smaller in absolute terms and its market demographics (median HHI ~$64K vs. $81K national) may amplify the impact vs. HCA's more diverse footprint. |
Surgical Volume Softness | Same-store surgeries declined 0.1% overall, with inpatient surgeries down 3.8%. Procedural softness concentrated in elective procedures: orthopedics (hip/knee/shoulder replacements) and cardiac surgeries. Outpatient surgeries increased but for lower-acuity procedures. Clinic visits and MRIs are not converting to surgeries — patients are delaying follow-on procedures. June was the best month of the quarter with positive YoY improvement. | Directly relevant to HCA's Q2 preliminary data showing inpatient surgeries −2.3% and outpatient surgeries −3.4%. The orthopedic/cardiac softness pattern and the 'screening-to-surgery conversion failure' dynamic are likely present in HCA's markets. The improving June exit rate is a modest positive signal for Q3. | HCA's outpatient surgery decline (−3.4%) is worse than CYH's, suggesting HCA may have greater exposure to the specific elective procedure categories under pressure. |
Payer Mix / Uninsured Volume | Approximately half of Q2 adjusted admissions growth (+2.9%) was from uninsured patients with minimal net revenue. Self-pay visits increased from ~5% to just over 6% of visits YoY (~110 bps or ~20% increase). Q2 saw a greater increase in self-pay than Q1. Medicaid volumes also declining, potentially contributing to uninsured growth. More bronze-plan enrollment observed vs. prior year. | Confirms HCA's payer-mix deterioration narrative. The 'volume growth masking revenue quality deterioration' dynamic is directly applicable — HCA's +2.7% equivalent admissions growth likely includes a meaningful uninsured component. The bronze-plan shift observation aligns with HCA's Q1 commentary on metal-tier migration. | HCA has greater scale and market power in its geographies, which may provide some pricing offset. HCA's specific exchange exposure by state will differ from CYH's footprint. |
Consumer Affordability / Commercial Demand | Softness in elective procedures among commercially insured patients attributed to consumer insecurity: geopolitical instability, inflation, rising gas prices. Consumer Confidence Index at 12-month low (similar to COVID levels). Healthcare is 'one of the first things people will delay.' Copays and deductibles are a barrier for commercially insured patients. | Relevant but partially mitigated for HCA given its higher-income market mix. However, the deductible/copay barrier to elective procedures is universal and likely contributing to HCA's surgical volume declines. If consumer confidence remains depressed, H2 surgical recovery may be slower than management's base case. | CYH's markets have lower median household income (~$64K vs. $81K national), making them more sensitive to consumer affordability pressures than HCA's typical market. |
Labor Costs | Same-store average hourly rate +1.1% YoY; contract labor spend down 5.6% same-store. However, medical specialist fees increased ~19% YoY same-store (5.6% of net revenue vs. 4.8% prior year), driven by anesthesiology and radiology. Anesthesia subsidies rising because fewer surgeries reduce anesthesiologist net revenue against guaranteed minimums. | The specialist fee dynamic is directly relevant to HCA: if surgical volumes are soft, anesthesia and other specialist subsidy costs rise mechanically. HCA guided to high-single-digit growth in hospital-based physician services for 2026 — the CYH data suggests this may be conservative if surgical volumes remain depressed. | HCA's scale and employed physician model may provide more flexibility than CYH's contracted specialist arrangements. HCA's overall labor cost management has been stronger historically. |
Payer Behavior / Denials / AR | Payers are now auditing more claims before payment (previously post-payment), slowing the payment process. AR days are growing as a result. CYH views this as a timing issue, not a collection issue, but cash flow is impacted in the near term. | Consistent with HCA's Q1 commentary on elevated denial and underpayment activity, particularly in Medicare Advantage. If payers are systematically shifting to pre-payment audits, HCA's AR and cash flow could face similar near-term pressure despite its stronger revenue cycle capabilities. | HCA has invested heavily in AI-driven revenue cycle tools (denial appeals, peer-to-peer prep) that may provide a competitive advantage in managing this dynamic vs. CYH. |
Supplemental Payments | CYH recognized benefits from newly approved Florida and Indiana state-directed payment programs in Q2 2026 (~$40–$45M combined EBITDA contribution, of which ~$20–$25M related to prior periods). Arizona program had a ~$15M reduction. Full-year guidance includes Georgia, Indiana, and Florida program benefits, but these are more than offset by ACA and macro headwinds. | Confirms that Florida DPP approval is a real and material benefit for hospital operators in Q2 2026 — consistent with HCA's ~$400M Q2 supplemental payment benefit. The 'prior period catch-up' nature of these payments (not recurring run-rate) is an important nuance for modeling H2 2026. | HCA's Florida exposure and supplemental payment structure differ from CYH's. HCA's $400M Q2 benefit is proportionally much larger and covers a longer catch-up period (Oct 2024–Jun 2026). |
H2 2026 Outlook | CYH is taking a cautious stance on H2 2026. Revised guidance assumes a similar impact in H2 as H2 experienced in H1, with continued softness in elective surgeries. The high end of guidance assumes some commercial volume recovery as deductibles are met in Q3/Q4; the low end assumes continued deferral into 2027. | The 'deductible reset' dynamic (commercial patients more likely to pursue elective procedures after meeting annual deductibles in Q3/Q4) is a potential positive catalyst for HCA in H2. However, CYH's cautious base case suggests this recovery is not guaranteed and may be modest. | HCA's H2 assumptions will be disclosed on the July 24 call. HCA's market mix and outpatient network density may provide more resilience than CYH's inpatient-heavy portfolio. |
THC reported solid Q2 2026 upside on sales and EBITDA and raised full-year guidance, also announcing a $2B buyback increase. THC cited strong same-store revenue growth and effective expense management. THC's outperformance relative to HCA's guidance cut is notable but should be interpreted with caution: THC's business mix is more heavily weighted toward ambulatory surgery centers (ASCs) and outpatient services, which are structurally less exposed to ACA exchange disenrollment than HCA's inpatient-heavy network. A full transcript read-through was not available as of July 23, 2026; the above is based on news digest reporting. HCA Read-Through: THC's beat suggests that not all hospital operators are equally impacted by the exchange headwind, and that operators with greater outpatient/ASC exposure may be better insulated. This is consistent with HCA's own strategic pivot toward outpatient network density (target: 20 outpatient sites per hospital). Limitation: THC's business model, geographic footprint, and payer mix differ materially from HCA's; direct financial comparison is not appropriate.
Key Takeaway: No open-market insider purchases or sales (Form 4 codes P/S) were identified for HCA in the period from April 24 to July 23, 2026, based on available SEC Form 4 data. The absence of insider buying during a ~13% stock decline is notable but not necessarily alarming given HCA's typical insider transaction patterns and the existence of pre-planned 10b5-1 programs.
Name | Title | Transaction Type | Value | Date | Note |
N/A — No open-market transactions identified | — | — | — | — | No Form 4 P/S transactions found in the Apr 24 – Jul 23, 2026 window |
Note: The SEC Form 4 database query for HCA covering April 24 – July 23, 2026 returned no open-market buy (P) or sell (S) transactions. This may reflect the existence of pre-planned 10b5-1 trading programs (which would appear as planned sales rather than discretionary transactions), a quiet period ahead of the July 24 earnings call, or simply the absence of discretionary insider activity during this window. The departure of Chief Clinical Officer Dr. Michael Cuffe (announced June 18, 2026) did not appear to be accompanied by any disclosed Form 4 transactions in the available data.
Key Takeaway: The call is effectively a post-preannouncement debrief. The market already knows the Q2 numbers; what it needs is management's framework for the H2 exchange headwind trajectory, the surgical volume recovery path, and whether the $28.70–$30.50 EPS range is a floor or a ceiling.